Related Experiment Video
Updated: Jan 20, 2026

Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes
Published on: July 4, 2007
ELQ-331 as a prototype for extremely durable chemoprotection against malaria.
Martin J Smilkstein1, Sovitj Pou2, Alina Krollenbrock3
1VA Portland Health Care System Research and Development Service, 3710 SW US Veterans Hospital Road, RD-33, Portland, OR, 97239, USA. smilkste@ohsu.edu.
Long-acting injectable chemoprotection (LAI-C) shows promise for malaria prevention. ELQ-331, a novel drug, provided sustained protection in mice for over 4 months, suggesting its potential for malaria LAI-C.
Area of Science:
- Pharmacology
- Infectious Diseases
- Drug Development
Background:
- Long-acting injectable chemoprotection (LAI-C) is emerging as a vital strategy for malaria prevention.
- ELQ-331, a prodrug of ELQ-300, was investigated for its potential as an LAI-C agent due to its favorable pharmacokinetic and pharmacodynamic properties.
Purpose of the Study:
- To evaluate the pharmacokinetics and efficacy of ELQ-331 as a long-acting injectable chemoprotection (LAI-C) against malaria in a mouse model.
- To determine the duration of protective effect and safety profile of ELQ-331 following a single intramuscular injection.
Main Methods:
- Four trials involving single intramuscular injections of ELQ-331 and other ELQ-300 prodrugs in mice.
- Efficacy assessed via challenge with Plasmodium yoelii sporozoites and whole-body live animal imaging.
- Pharmacokinetic analysis of ELQ-331 and ELQ-300 plasma concentrations over time.
Main Results:
- A single dose of ELQ-331 protected mice against P. yoelii sporozoite challenge for at least 4.5 months.
- ELQ-331 demonstrated rapid conversion to ELQ-300, achieving sustained therapeutic concentrations for 4-5 months.
- Pharmacokinetic modeling revealed a tissue compartment facilitating slow redistribution of ELQ-300, maintaining protective levels.
Conclusions:
- ELQ-331 shows significant potential to meet and exceed current duration-of-effect goals for anti-malarial LAI-C.
- The unique pharmacokinetic profile of ELQ-300 derived from ELQ-331 may offer durable malaria protection.
- ELQ-331 is a promising candidate for further development as a leading anti-malarial LAI-C agent.
More Related Videos
Related Concept Videos
Concepts and Prototypes
The brain organizes this information using concepts, which are mental categories grouping linguistic data,...
Brick Durability, Strength, and Appearance
Absolute and Local Extreme Values
The Representativeness Heuristic
Regression Toward the Mean
Specific Heat
For example, increasing the temperature of one gram of water by 1°C requires one calorie of heat energy and can be written as 1 cal/g-°C, or...

